Zerion Pharma elects Carl-Åke Carlsson to its Board of Directors as Chairman

– DENMARK, Copenhagen –  Zerion Pharma A/S today announced the election of Carl-Åke Carlsson as its new Chairman of the Board of Directors.

About Carl-Åke Carlsson

Carl-Åke Carlsson brings over three decades of leadership and strategic experience in the pharmaceutical industry and embodies Scandinavian diversity: Born in Norway with Swedish ancestry, he has spent over a decade living and working in Denmark.

He is joining Zerion’s Board after 15 years as CEO of Xellia Pharmaceuticals, specializing in anti-infective and critical care treatments. Under his leadership, Xellia transitioned from a Scandinavian entity to a global contender, boasting annual sales of USD 300 million and a robust team of around 1,800 employees.

Mr. Carlsson held several leadership roles at Alpharma (NYSE: ALO). For a decade, he was integral to the top leadership, overseeing business within pharmaceutical retail, specialty institutional markets, and the extensive global B2B sectors. Mr. Carlsson is also serving in prominent board positions, including the biotech company Vectron Biosolutions and Lecka Alpha Trading LP.

About Zerion Pharma A/S

ZERION develops its own proprietary drug formulations and offers its Dispersome technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION’s technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients.

ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research.

SOURCE: https://www.zerion.eu/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.